Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Takeda and Amylin terminate worldwide agreement

Dec. 28, 2012

Once-monthly formulation of antiosteoporotic agent approved in Japan

Dec. 27, 2012

FDA approves Juxtapid for homozygous familial hypercholesterolemia

Dec. 27, 2012

Raptor Pharmaceutical provides update on NDA review for Procysbi

Dec. 27, 2012

Ranbaxy Laboratories presents new DPP IV inhibitor for the treatment of diabetes

Dec. 27, 2012

Novel agents for obesity disclosed by GlaxoSmithKline

Dec. 27, 2012

Catabasis Pharmaceuticals presents new GABA conjugates

Dec. 27, 2012

Novo Nordisk provides update on three clinical development programs

Dec. 24, 2012

Janssen Pharmaceutica prepares novel glucagon receptor antagonists

Dec. 24, 2012

German researchers patent novel anti-PRL-R antibody

Dec. 24, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...